Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA4 | P22748 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4708831 | 1.00 | CA1 (0.56) | CA1CA2CA4CA9LMNA | |
| SCHEMBL2014666 | 1.00 | CA1 (0.56) | CA1CA2CA4CA9LMNA | |
| SCHEMBL9101358 | 0.95 | CA1 (0.52) | CA1CA2CA4CA9LMNA | |
| Piperazine SCHEMBL9028960 | 0.95 | CA1 (0.52) | CA1CA2CA4CA9LMNA | |
| Piperazine SCHEMBL9028956 | 0.95 | CA1 (0.52) | CA1CA2CA4CA9LMNA | |
| SCHEMBL19878826 | 0.94 | CA1 (0.50) | CA1CA2CA4CA9LMNA | |
| SCHEMBL19878828 | 0.94 | CA1 (0.50) | CA1CA2CA4CA9LMNA | |
| SCHEMBL8575175 | 0.93 | CA1 (0.49) | CA1CA2CA4CA9LMNA | |
| SCHEMBL13705078 | 0.93 | CA1 (0.49) | CA1CA2CA4CA9LMNA | |
| SCHEMBL15020095 | 0.91 | NR1H2 (0.47) | CA1CA2CA4CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775260-A | Pyrimidine-2, 4 (1H, 3H) -dione compounds, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2025-04-08 | — | — | CN | disclosed |
| US-11608339-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| EP-3500570-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-109952301-B | 5-HT2C receptor agonists and compositions and methods of use | 艾尼纳制药公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20210214355-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10836764-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| EP-3636651-A1 | HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-04-15 | — | — | EP | disclosed |
| US-20190225612-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2019-07-25 | — | — | US | disclosed |
| EP-3500570-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | Arena Pharmaceuticals, Inc. (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20180339996-A1 | HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-11-29 | — | — | US | disclosed |
| EP-3380483-A1 | HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS | Abbvie Deutschland GmbH & Co. KG (DE) | 2018-10-03 | — | — | EP | disclosed |
| WO-2018035477-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2017089458-A1 | HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-01 | — | — | WO | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | CA1 2606/4885CA2 1023/4885CA4 1470/4885 |
| US-20190225612-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, TPH2 | CA1 4527/4885CA2 4160/4885CA4 4730/4885 |
| US-20180339996-A1 | HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS | HTR2C, HTR2A, HTR5A | CA1 3323/4885CA2 1508/4885CA4 3989/4885 |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CA1 2275/4885CA2 218/4885CA4 296/4885 |
| US-11608339-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, TPH2 | CA1 4529/4885CA2 4052/4885CA4 4765/4885 |
| US-20210214355-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, TPH2 | CA1 4425/4885CA2 3925/4885CA4 4713/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CA1 2275/4885CA2 218/4885CA4 296/4885 |
| US-10836764-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, TPH2 | CA1 4529/4885CA2 4052/4885CA4 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.